Reference values of serum calcitonin with calcium stimulation tests by electrochemiluminescence immunoassay before/after total thyroidectomy in Japanese patients with thyroid diseases other than medullary thyroid carcinoma.

Calcitonin is a very sensitive tumor marker of medullary thyroid carcinoma (MTC). MTC patients usually have very high values of serum calcitonin that can be used to diagnose the disease. To improve the diagnostic sensitivity in family members with small MTCs and to evaluate the postoperative biochemical cure status, a calcium stimulation test is widely used. Serum calcitonin has been measured using several methods, but in Japan, only an electrochemiluminescence immunoassay (ECLIA) is currently performed to determine serum calcitonin. Reference values for the calcium stimulation test using an ECLIA have not been reported. Here we conducted a calcium stimulation tests in 26 patients without MTC before and after total thyroidectomy. Preoperatively, the basal calcitonin values of all patients were within normal limits and increased to a mean of 14.4 pg/mL after calcium stimulation. We transformed the peak values before total thyroidectomy to a logarithmic distribution and calculated the normalized mean ± 1.96× standard deviation; the reference upper limit was thus expressed. In the female patients with non-MTC, the reference upper limit was 67.6 pg/mL. In all patients, the calcium stimulation test results after total thyroidectomy showed undetectable basal and stimulated calcitonin values (<0.5 pg/mL). This is the first study to determine reference values to be used for the calcium stimulation test along with an ECLIA in non-MTC patients. We propose that female patients are regarded as biochemically cured or normal when the stimulated calcitonin values by ECLIA are <67.6 pg/mL before surgery and <0.5 pg/mL after total thyroidectomy.

[1]  G. Papadakis,et al.  Association of Basal and Calcium-stimulated Calcitonin Levels with Pathological Findings After Total Thyroidectomy. , 2015, Anticancer research.

[2]  Douglas B. Evans,et al.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. , 2015, Thyroid : official journal of the American Thyroid Association.

[3]  R. Marculescu,et al.  Low-dose calcium versus pentagastrin for stimulation of calcitonin in chronic hemodialysis patients: a pilot study. , 2014, The Journal of clinical endocrinology and metabolism.

[4]  M. Pelizzo,et al.  Refining calcium test for the diagnosis of medullary thyroid cancer: cutoffs, procedures, and safety. , 2014, The Journal of clinical endocrinology and metabolism.

[5]  K. Tziomalos,et al.  Calcitonin stimulation tests for the early diagnosis and follow-up of patients with C cell disease: a descriptive analysis. , 2013, Hippokratia.

[6]  H. Holzhausen,et al.  Hypercalcitoninemia in thyroid conditions other than medullary thyroid carcinoma: a comparative analysis of calcium and pentagastrin stimulation of serum calcitonin , 2013, Langenbeck's Archives of Surgery.

[7]  L. Fugazzola Stimulated Calcitonin Cut-Offs by Different Tests , 2013, European Thyroid Journal.

[8]  M. Alevizaki,et al.  2012 European Thyroid Association Guidelines for Genetic Testing and Its Clinical Consequences in Medullary Thyroid Cancer , 2012, European Thyroid Journal.

[9]  M. Pelizzo,et al.  Comparison of calcium and pentagastrin tests for the diagnosis and follow-up of medullary thyroid cancer. , 2012, The Journal of clinical endocrinology and metabolism.

[10]  L. Giovanella Serum procalcitonin and calcitonin normal values before and after calcium gluconate infusion. , 2012, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[11]  Kiyoshi Ichihara,et al.  An appraisal of statistical procedures used in derivation of reference intervals , 2010, Clinical chemistry and laboratory medicine.

[12]  B. Nilsson,et al.  Can the early reduction of tumour markers predict outcome in surgically treated sporadic medullary thyroid carcinoma? , 2008, Langenbeck's Archives of Surgery.

[13]  B. Wolffenbuttel,et al.  Determinants of life expectancy in medullary thyroid cancer: age does not matter , 2006, Clinical endocrinology.

[14]  E. Mirallié,et al.  Central neck dissection in the management of sporadic medullary thyroid microcarcinoma. , 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[15]  L. Sobrinho,et al.  Preoperative diagnosis of medullary thyroid carcinoma: Fine needle aspiration cytology as compared with serum calcitonin measurement , 2005, Journal of surgical oncology.

[16]  E. Baudin,et al.  Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging , 2003, British Journal of Cancer.

[17]  M. Fowler,et al.  Normal preoperative calcitonin levels do not always exclude medullary thyroid carcinoma in patients with large palpable thyroid masses. , 2000, Thyroid : official journal of the American Thyroid Association.

[18]  C. Lombardi,et al.  Intraoperative high-dose calcium stimulation test in patients with sporadic medullary thyroid carcinoma is highly accurate in predicting lateral neck metastases. , 2016, Surgery.

[19]  Kathryn J. Rowland,et al.  Biochemical Cure after Reoperations for Medullary Thyroid Carcinoma: A Meta-analysis , 2014, Annals of Surgical Oncology.

[20]  M. Alevizaki,et al.  European Thyroid Association Guidelines for Genetic Testing and Its Clinical Consequences in Medullary Thyroid Cancer , 2013 .

[21]  A. Miyauchi,et al.  Serum calcitonin levels with calcium loading tests before and after total thyroidectomy in patients with thyroid diseases other than medullary thyroid carcinoma. , 2011, Endocrine journal.

[22]  A. Miyauchi,et al.  Alternative Surgical Strategies and Favorable Outcomes in Patients with Medullary Thyroid Carcinoma in Japan: Experience of a Single Institution , 2008, World Journal of Surgery.